X Bioscience PCL Statistics

Total Valuation

BKK:XBIO has a market cap or net worth of THB 230.77 million. The enterprise value is 890.05 million.

Market Cap	230.77M
Enterprise Value	890.05M

Important Dates

The next estimated earnings date is Tuesday, May 13, 2025.

Earnings Date	May 13, 2025
Ex-Dividend Date	n/a

Share Statistics

BKK:XBIO has 2.10 billion shares outstanding. The number of shares has increased by 46.89% in one year.

Current Share Class	n/a
Shares Outstanding	2.10B
Shares Change (YoY)	+46.89%
Shares Change (QoQ)	+56.66%
Owned by Insiders (%)	22.59%
Owned by Institutions (%)	n/a
Float	1.57B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.72
PB Ratio	0.28
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.42
EV / Sales	2.79
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.06

Financial Position

The company has a current ratio of 0.25, with a Debt / Equity ratio of 0.43.

Current Ratio	0.25
Quick Ratio	0.14
Debt / Equity	0.43
Debt / EBITDA	n/a
Debt / FCF	-4.81
Interest Coverage	-7.33

Financial Efficiency

Return on equity (ROE) is -51.88% and return on invested capital (ROIC) is -17.64%.

Return on Equity (ROE)	-51.88%
Return on Assets (ROA)	-14.58%
Return on Invested Capital (ROIC)	-17.64%
Return on Capital Employed (ROCE)	-25.61%
Revenue Per Employee	800,109
Profits Per Employee	-652,192
Employee Count	399
Asset Turnover	0.30
Inventory Turnover	19.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.81% in the last 52 weeks. The beta is 1.43, so BKK:XBIO's price volatility has been higher than the market average.

Beta (5Y)	1.43
52-Week Price Change	-82.81%
50-Day Moving Average	0.18
200-Day Moving Average	0.49
Relative Strength Index (RSI)	35.39
Average Volume (20 Days)	3,993,267

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BKK:XBIO had revenue of THB 319.24 million and -260.22 million in losses. Loss per share was -0.20.

Revenue	319.24M
Gross Profit	138.61M
Operating Income	-251.21M
Pretax Income	-277.92M
Net Income	-260.22M
EBITDA	-224.53M
EBIT	-251.21M
Loss Per Share	-0.20

Full Income Statement

Balance Sheet

The company has 9.19 million in cash and 354.56 million in debt, giving a net cash position of -345.37 million or -0.16 per share.

Cash & Cash Equivalents	9.19M
Total Debt	354.56M
Net Cash	-345.37M
Net Cash Per Share	-0.16
Equity (Book Value)	827.43M
Book Value Per Share	0.26
Working Capital	-326.09M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -37.44 million and capital expenditures -36.33 million, giving a free cash flow of -73.77 million.

Operating Cash Flow	-37.44M
Capital Expenditures	-36.33M
Free Cash Flow	-73.77M
FCF Per Share	-0.04

Full Cash Flow Statement

Margins

Gross margin is 43.42%, with operating and profit margins of -78.69% and -81.51%.

Gross Margin	43.42%
Operating Margin	-78.69%
Pretax Margin	-87.05%
Profit Margin	-81.51%
EBITDA Margin	-70.33%
EBIT Margin	-78.69%
FCF Margin	n/a

Dividends & Yields

BKK:XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-46.89%
Shareholder Yield	-46.89%
Earnings Yield	-112.76%
FCF Yield	-31.97%

Stock Splits

The last stock split was on May 5, 2021. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	May 5, 2021
Split Type	Reverse
Split Ratio	0.0666666667

Scores

BKK:XBIO has an Altman Z-Score of -1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.17
Piotroski F-Score	n/a